Skip to main content
SpringerLink
Log in

A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

One-third of older adults with depression meet criteria for treatment resistance, typically defined as a lack of response to two or more adequate trials of an antidepressant. Treatment resistance contributes to an unfavorable prognosis, compromised medical outcomes, heightened disability, accelerated cognitive decline, and an elevated risk of developing dementia. Despite this significant morbidity, evidence is sparse for how to proceed with treatment in this population. Non-pharmacologic therapy (e.g., diet, psychotherapy) can be utilized as adjunctive therapy, despite little published evidence of benefit, given that the risks are low. Pharmacotherapy trials in the treatment-resistant late-life depression population lack strong methods and external validity; however, the use of venlafaxine as monotherapy and add-on therapy, as well as lithium, bupropion, or aripiprazole as add-on therapy to standard antidepressant therapy, have enough evidence that a trial with appropriate monitoring is a prudent strategy. Electroconvulsive therapy remains a well-studied safe therapy, especially when used as maintenance treatment once an initial cycle is completed but is traditionally underutilized in the treatment-resistant late-life depression population. Ensuring non-pharmacologic and pharmacologic strategies are optimized and given a sufficient trial in those with treatment-resistant late-life depression is the best we can do for this vulnerable population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Psychiatric Association: Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013.

  2. Panza F, Frisardi V, Capurso C, et al. Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am J Geriatr Psychiatry. 2010;18(2):98–116. https://doi.org/10.1097/JGP.0b013e3181b0fa13.

    Article  PubMed  Google Scholar 

  3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D Report. Am J Psychiatry. 2006;163(11):1905–17. https://doi.org/10.1176/ajp.2006.163.11.1905.

    Article  PubMed  Google Scholar 

  4. McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7. https://doi.org/10.1016/j.jad.2013.10.043.

    Article  CAS  PubMed  Google Scholar 

  5. Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(Suppl. 13):23–9.

    PubMed  Google Scholar 

  6. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1–2): 83–91. https://doi.org/10.1016/s0924-977x(98)00004-2.

    Article  CAS  PubMed  Google Scholar 

  7. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649–59. https://doi.org/10.1016/s0006-3223(03)00231-2.

    Article  PubMed  Google Scholar 

  8. Fekadu A, Wooderson S, Donaldson C, et al. A multidimensional tool to quantify treatment resistance in depression; the Maudsley staging method. J Clin Psychiatry. 2009;70(2):177–84. https://doi.org/10.4088/jcp.08m04309.

    Article  PubMed  Google Scholar 

  9. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(Suppl. 6):16–22.

    PubMed  Google Scholar 

  10. Eaton WW, Shao H, Nestadt G, et al. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008;65(5):513–20. https://doi.org/10.1001/archpsyc.65.5.513.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Stek ML, Exel EV, Tilburg WV, et al. The prognosis of depression in old age: outcome six to eight years after clinical treatment. Aging Ment Health. 2002;6(3):282–85. https://doi.org/10.1080/13607860220142413.

    Article  CAS  PubMed  Google Scholar 

  12. Iosifescu DV, Nierenberg AA, Alpert JE, et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry. 2003;160(12):2122–7. https://doi.org/10.1176/appi.ajp.160.12.2122.

    Article  PubMed  Google Scholar 

  13. Pimontel MA, Rindskopf D, Rutherford BR, et al. A meta-analysis of executive dysfunction and antidepressant treatment response in late-life depression. Am J Geriatr Psychiatry. 2016;24(1):31–41. https://doi.org/10.1016/j.jagp.2015.05.010.

    Article  PubMed  Google Scholar 

  14. Licht-Strunk E, van der Windt D, van Marwijk H, et al. The prognosis of depression in older patients in general practice and the community: a systematic review. Fam Pract. 2007;24(2):168–80. https://doi.org/10.1093/fampra/cml071.

    Article  PubMed  Google Scholar 

  15. Zivin K, Yosef M, Miller EM, et al. Associations between depression and all-cause and cause-specific risk of death: a retrospective cohort study in the Veterans Health Administration. J Psychosom Res. 2015;78(4):324–31. https://doi.org/10.1016/j.jpsychores.2015.01.014.

    Article  PubMed  Google Scholar 

  16. Steenland K, Karnes C, Seals R, et al. Late-life depression as a risk factor for mild cognitive impairment or Alzheimer’s disease in 30 US Alzheimer’s disease centers. J Alzheimers Dis. 2012;31(2):265–75. https://doi.org/10.3233/JAD-2012-111922.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Richard E, Reitz C, Honig LH, et al. Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol. 2013;70(3):374–82. https://doi.org/10.1001/jamaneurol.2013.603.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Saczynski JS, Beiser A, Seshadri S, et al. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology. 2010;75(1):35–41. https://doi.org/10.1212/WNL.0b013e3181e62138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Diniz BS, Butters MA, Albert SM, et al. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202(5):329–35. https://doi.org/10.1192/bjp.bp.112.118307.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Pilon D, Joshi K, Sheehan JJ, et al. Burden of treatment-resistant depression in Medicare: a retrospective claims database analysis. PLoS ONE. 2019;14(10):e0223255. https://doi.org/10.1371/journal.pone.0223255.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. American Psychological Association. Clinical practice guideline for the treatment of depression across three age cohorts. 2019. https://www.apa.org/depression-guideline. Accessed 6 Oct 2022.

  22. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE Guideline. 2022. https://www.nice.org.uk/guidance/ng222. Accessed 6 Oct 2022.

  23. MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. Can J Psychiatry. 2016;61(9):588–603. https://doi.org/10.1177/0706743716659276.

  24. Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle age: a systematic review of comparative studies. Am J Psychiatry. 2005;162:1588–601. https://doi.org/10.1176/appi.ajp.162.9.1588.

    Article  PubMed  Google Scholar 

  25. Pennix BWJH, Guralnik JM, Mendes de Leon CF, et al. Cardiovascular events and mortality in newly and chronically depressed persons > 70 years of age. Am J Cardiol. 1998;81(8):988–94. https://doi.org/10.1016/s0002-9149(98)00077-0.

  26. Baldwin RC, Gallagley A, Gourlay M, et al. Prognosis of late life depression: a three-year cohort study of outcome and potential predictors. Int J Geriatr Psychiatry. 2006;21(1):57–63. https://doi.org/10.1002/gps.1424.

    Article  PubMed  Google Scholar 

  27. Huang AX, Delucchi K, Dunn LB, et al. A systematic review and meta-analysis of psychotherapy for late-life depression. Am J Geriatr Psychiatry. 2015;23:261–73. https://doi.org/10.1016/j.jagp.2014.04.003.

    Article  PubMed  Google Scholar 

  28. Kirkham JG, Choi N, Seitz DP. Meta-analysis of problem solving therapy for the treatment of major depressive disorder in older adults. Int J Geriatr Psychiatry. 2016;31:526–35. https://doi.org/10.1002/gps.4358.

    Article  PubMed  Google Scholar 

  29. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551. https://doi.org/10.1136/bmj.d4551.

    Article  PubMed  PubMed Central  Google Scholar 

  30. American Geriatrics Society. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023. https://doi.org/10.1111/jgs.18372.

  31. Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord. 2012;141(2–3):103–15. https://doi.org/10.1016/j.jad.2012.02.036.

    Article  CAS  PubMed  Google Scholar 

  32. Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008;16(7):558–67. https://doi.org/10.1097/JGP.0b013e3181693288.

    Article  PubMed  Google Scholar 

  33. Tollefson GD, Bosomworth JC, Heiligenstein JH, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. Int Psychogeriatr. 1995;7(1):89–104. https://doi.org/10.1017/s1041610295001888.

    Article  CAS  PubMed  Google Scholar 

  34. Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry. 2003;64(9):1065–74. https://doi.org/10.4088/jcp.v64n0912.

    Article  CAS  PubMed  Google Scholar 

  35. Schneider LS, Nelson JC, Clary CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry. 2003;160(7):1277–85. https://doi.org/10.1176/appi.ajp.160.7.1277.

    Article  PubMed  Google Scholar 

  36. Rapaport MH, Lydiard RB, Pitts CD, et al. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. J Clin Psychiatry. 2009;70(1):46–57. https://doi.org/10.4088/jcp.06m02996.

    Article  CAS  PubMed  Google Scholar 

  37. Thorlund K, Druyts E, Wu P, et al. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc. 2015;63(5):1002–9. https://doi.org/10.1111/jgs.13395.

    Article  PubMed  Google Scholar 

  38. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164(6):900–9. https://doi.org/10.1007/s40266-012-0040-1.

    Article  CAS  PubMed  Google Scholar 

  39. Hewett K, Chrzanowski W, Jokinen R, et al. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder. J Psychopharmacol. 2010;24(4):521–9.

    Article  CAS  PubMed  Google Scholar 

  40. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–23. https://doi.org/10.1097/YIC.0b013e3283542457.

    Article  PubMed  Google Scholar 

  41. Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry. 1986;21(12):1155–66. https://doi.org/10.1016/0006-3223(86)90222-2.

    Article  CAS  PubMed  Google Scholar 

  42. Schweizer E, Rickels K, Hassman H, et al. Buspirone and imipramine for the treatment of major depression in the elderly. J Clin Psychiatry. 1998;59(4):175–83. https://doi.org/10.4088/jcp.v59n0406.

    Article  CAS  PubMed  Google Scholar 

  43. Unutzer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288(22):2836–45. https://doi.org/10.1001/jama.288.22.2836.

    Article  PubMed  Google Scholar 

  44. Alexopoulos GS, Katz IR, Bruce ML, et al. Remission in depressed geriatric primary care patients: a report from the PROSPECT study. Am J Psychiatry. 2005;162(4):718–24. https://doi.org/10.1176/appi.ajp.162.4.718.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Kok RM, Heeren TJ, Nolen WA. Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. Am J Geriatr Psychiatry. 2011;19(3):249–55. https://doi.org/10.1097/jgp.0b013e3181ec8085.

    Article  PubMed  Google Scholar 

  46. Ljungberg T, Bondza E, Lethin C. Evidence of the importance of dietary habits regarding depressive symptoms and depression. Int J Environ Res Public Health. 2020;17(5):1616. https://doi.org/10.3390/ijerph17051616.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Masana MF, Haro JM, Mariolis A, et al. Mediterranean diet and depression among older individuals: the multinational MEDIS study. Exp Gerontol. 2018;110:67–72. https://doi.org/10.1016/j.exger.2018.05.012.

    Article  PubMed  Google Scholar 

  48. Saeed SA, Cunningham K, Bloch RM. Depression and anxiety disorders: benefits of exercise, yoga, and meditation. Am Fam Physician. 2019;99:620–7.

    PubMed  Google Scholar 

  49. Murri MB, Amore M, Menchetti M, et al. Physical exercise for late-life major depression. Br J Psychiatry. 2015;207(3):235–42. https://doi.org/10.1192/bjp.bp.114.150516.

    Article  Google Scholar 

  50. Murri MB, Ekkekakis P, Menchetti M, et al. Physical exercise for late-life depression: effects on symptom dimensions and time course. J Affect Disord. 2018;230:65–70. https://doi.org/10.1016/j.jad.2018.01.004.

    Article  PubMed  Google Scholar 

  51. Schuch FB, Vancampfort D, Rosenbaum S, et al. Exercise for depression in older adults: a meta-analysis of randomized controlled trials adjusting for publication bias. Braz J Psychiatry. 2016;38(3):247–54. https://doi.org/10.1590/1516-4446-2016-1915.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Knöchel C, Alves G, Friedrichs B, et al. Treatment-resistant late life depression: challenges and perspectives. Curr Neuropharmacol. 2015;13:577–91. https://doi.org/10.2174/1570159X1305151013200032.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92–107. https://doi.org/10.1002/wps.20701.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Hollon SD, Jarrett RB, Nierenberg AA, et al. Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? J Clin Psychiatry. 2005;66(4):455–68. https://doi.org/10.4088/jcp.v66n0408.

    Article  PubMed  Google Scholar 

  55. Li JM, Zhang Y, Su WJ, et al. Cognitive behavioral therapy for treatment-resistant depression: a systematic review and meta-analysis. Psychiatry Res. 2018;268:243–50. https://doi.org/10.1016/j.psychres.2018.07.020.

    Article  PubMed  Google Scholar 

  56. Sadler P, McLaren S, Klein B, et al. Cognitive behavior therapy for older adults with insomnia and depression: a randomized controlled trial in community mental health services. Sleep. 2018;41(8).  https://doi.org/10.1093/sleep/zsy104.

  57. Raue PJ, McGovern AR, Kiosses DN, et al. Advances in psychotherapy for depressed older adults. Curr Psychiatry Rep. 2017;19(9):57. https://doi.org/10.1007/s11920-017-0812-8.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Rush AJ, Trivedi MH, Wisniewski SR, et al. STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;163(11):1905–17. https://doi.org/10.1056/NEJMoa052963.

  59. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment resistant depression: double-blind, randomised comparison. Br J Psychiatry. 1999;175:12–6. https://doi.org/10.1192/bjp.175.1.12.

    Article  CAS  PubMed  Google Scholar 

  60. Mitchell PB, Schweitzer I, Burrows G, et al. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol. 2005;162:1588–601. https://doi.org/10.1097/00004714-200008000-00014.

    Article  Google Scholar 

  61. Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther. 2002;24(7):1194–200. https://doi.org/10.1016/s0149-2918(02)80029-7.

    Article  CAS  PubMed  Google Scholar 

  62. Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety. 2005;22(2):68–76. https://doi.org/10.1002/da.20080.

    Article  CAS  PubMed  Google Scholar 

  63. Ruhe HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006;67(12):1836–55. https://doi.org/10.4088/jcp.v67n1203.

    Article  CAS  PubMed  Google Scholar 

  64. Mazeh D, Shahal B, Aviv A, et al. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Int Clin Psychopharmacol. 2007;22:371–75. https://doi.org/10.1097/YIC.0b013e32817396ae.

    Article  PubMed  Google Scholar 

  65. Holroyd S, Durgee J. Venlafaxine in treatment refractory geriatric depression. Clin Gerontol. 1998;18(3):39–50. https://doi.org/10.1300/J018v18n03_05.

    Article  Google Scholar 

  66. Whyte EM, Basinski J, Fahri P, et al. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65(12):1634–41. https://doi.org/10.4088/jcp.v65n1208.

    Article  CAS  PubMed  Google Scholar 

  67. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737–48. https://doi.org/10.1038/sj.bjp.0707253.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Weintraub D. Nortriptyline in geriatric depression resistant to serotonin reuptake inhibitors: case series. J Geriatr Psychiatry Neurol. 2001;14(1):28–32. https://doi.org/10.1177/089198870101400107.

    Article  CAS  PubMed  Google Scholar 

  69. Lenze EJ, Mulsant BH, Roose SP, et al. Antidepressant augmentation versus switch in treatment-resistant geriatric depression. 2023;388(12):1067–79. https://doi.org/10.1056/NEJMoa2204462.

  70. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry. 1994;51(8):607–15.

    Article  CAS  PubMed  Google Scholar 

  71. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68(Suppl. 8):35–41.

    CAS  PubMed  Google Scholar 

  72. Culpepper L. Reducing the burden of difficult-to-treat major depressive disorder: revisiting monoamine oxidase inhibitor therapy. Prim Care Comp CNS Disord. 2013;15(5):PCC.13r01515. https://doi.org/10.4088/PCC.13r01515.

    Article  Google Scholar 

  73. Moirand R, Galvao F, Dondé C. Pramipexole and selegiline combination therapy in a case of treatment-resistant depression. J Clin Psychopharmacol. 2019;39(6):684–85. https://doi.org/10.1097/JCP.0000000000001139.

    Article  PubMed  Google Scholar 

  74. Kitaichi Y, Inoue T, Mitsui N, et al. Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report. Neuropsychiatr Dis Treat. 2013;9:1591–4. https://doi.org/10.2147/NDT.S49261.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Quante A, Zeugmann S. Tranylcypromine and bupropion combination therapy in treatment-resistant major depression: a report of 2 cases. J Clin Psychopharmacol. 2012;32(4):572–4. https://doi.org/10.1097/JCP.0b013e31825de0a7.

    Article  PubMed  Google Scholar 

  76. Bergman J, Miodownik C, Palatnik A, et al. Efficacy of bupropion XR in treatment-resistant elderly patients: a case series study. Clin Neuropharmacol. 2011;34(1):17–20. https://doi.org/10.1097/WNF.0b013e3182096f5a.

    Article  CAS  PubMed  Google Scholar 

  77. Szymkowicz SM, Finnegan N, Dale RM. Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder. J Clin Psychopharmacol. 2014;34(2):285–6. https://doi.org/10.1097/JCP.0000000000000090.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Bryant KA, Altinay M, Finnegan N, et al. Effects of repeated intravenous ketamine in treatment-resistant geriatric depression: a case series. J Clin Psychopharmacol. 2019;39(2):158–61. https://doi.org/10.1097/JCP.0000000000001006.

    Article  CAS  PubMed  Google Scholar 

  79. George D, Gálvez V, Martin D, et al. Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. Am J Geriatr Psychiatry. 2017;25(11):1199–209. https://doi.org/10.1016/j.jagp.2017.06.007.

    Article  PubMed  Google Scholar 

  80. Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28(2):121–41. https://doi.org/10.1016/j.jagp.2019.10.008.

    Article  PubMed  Google Scholar 

  81. Cooper C, Katona C, Lyketsos K, et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry. 2011;168:681–8. https://doi.org/10.1176/appi.ajp.2011.1008116.5.

    Article  PubMed  Google Scholar 

  82. Lafferman J, Solomon K, Ruskin P. Lithium augmentation for treatment-resistant depression in the elderly. J Geriatr Psychiatry Neurol. 1988;1(1):49–52. https://doi.org/10.1177/089198878800100109.

    Article  CAS  PubMed  Google Scholar 

  83. Finch EJL, Katona CLE. Lithium augmentation in the treatment of refractory depression in old age. Int J Geriatr Psychiatry. 1989;4:41–6. https://doi.org/10.1002/gps.930040110.

    Article  Google Scholar 

  84. Zimmer B, Rosen J, Thornton JE, et al. Adjunctive lithium carbonate in nortriptyline-resistant elderly depressed patients. J Clin Psychopharmacol. 1991;11(4):254–56. https://doi.org/10.1097/00004714-199108000-00006.

    Article  CAS  PubMed  Google Scholar 

  85. Kok RM, Vink D, Heeren TJ, et al. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial. J Clin Psychiatry. 2007;68(8):1177–85. https://doi.org/10.4088/jcp.v68n0803.

    Article  CAS  PubMed  Google Scholar 

  86. Dew MA, Whyte EM, Lenze EJ, et al. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry. 2007;164:892–99. https://doi.org/10.1176/ajp.2007.164.6.892.

    Article  PubMed  Google Scholar 

  87. Kok RM, Nolen WA, Heeren TJ. Outcome of late-life depression after 3 years of sequential treatment. Acta Psychiatr Scand. 2009;119:274–81. https://doi.org/10.1111/j.1600-0447.2008.01295.x.

    Article  CAS  PubMed  Google Scholar 

  88. Katz TC, Georgakas J, Motyl C, et al. Pharmacologic treatment of bipolar disorder in the elderly. Curr Treat Opt Psych. 2017;4:13–32. https://doi.org/10.1007/s40501-017-0101-5.

    Article  Google Scholar 

  89. Fraser SA, Kroenke K, Callahan CM, et al. Low yield of thyroid-stimulating hormone testing in elderly patients with depression. Gen Hosp Psychiatry. 2004;26(4):302–9. https://doi.org/10.1016/j.genhosppsych.2004.03.007.

    Article  PubMed  Google Scholar 

  90. Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dial Clin Neurosci. 2003;160(12): 2122–7. https://doi.org/10.31887/DCNS.2015.17.2/dionescu.

    Article  Google Scholar 

  91. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR* D report. Am J Psychiatry. 2006;163:1519–30. https://doi.org/10.1176/ajp.2006.163.9.1519.

    Article  PubMed  Google Scholar 

  92. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:43–53. https://doi.org/10.4088/jcp.v68n0604.

    Article  Google Scholar 

  93. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156–65. https://doi.org/10.1097/JCP.0b013e31816774f9.

    Article  CAS  PubMed  Google Scholar 

  94. Rutherford B, Sneed J, Miyazaki M, et al. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int J Geriatr Psychiatry. 2007;22(10):986–91. https://doi.org/10.1002/gps.1775.

    Article  PubMed  Google Scholar 

  95. Sweeney EB, Lawlor BA. Case series: extrapyramidal symptoms associated with use of aripiprazole in older adults. Int J Geriatr Psychiatry. 2013;28(11):1208–10. https://doi.org/10.1002/gps.3964.

    Article  PubMed  Google Scholar 

  96. Sheffrin M, Driscoll HC, Lenze EJ, et al. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. J Clin Psychiatry. 2009;70(2):208–13. https://doi.org/10.4088/jcp.07m03805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Lenze EJ, Mulsant BH, Blumberger DM, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(10011):2404–12. https://doi.org/10.1016/S0140-6736(15)00308-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Hsu JH, Mulsant BH, Lenze EJ, et al. Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. J Clin Psychiatry. 2018;79(4):17m11764. https://doi.org/10.4088/JCP.17m11764.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Smagula SF, Wallace ML, Anderson SJ, et al. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder. J Psychiatr Res. 2016;81:112–8. https://doi.org/10.1016/j.jpsychires.2016.07.005.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Kaneriya SH, Robbins-Welty GA, Smagula SF, et al. Predictors and moderators of remission with aripiprazole augmentation in treatment-resistant late-life depression: an analysis of the IRL-GRey randomized clinical trial. JAMA Psychiat. 2016;73(4):329–36. https://doi.org/10.1001/jamapsychiatry.2015.3447.

    Article  Google Scholar 

  101. Gebara MA, DiNapoli EA, Kasckow J, et al. Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression. Int J Geriatr Psychiatry. 2018;33(2):e330–5. https://doi.org/10.1002/gps.4813.

    Article  PubMed  Google Scholar 

  102. Bailey TA, Panjwani S. Atypical antipsychotics in late-life and treatment-resistant depression. Consult Pharm. 2018;33(2):83–8. https://doi.org/10.4140/TCP.n.2018.83.

    Article  Google Scholar 

  103. Pickett P, Massand P, Murray GB, et al. Psychostimulant treatment of geriatric depressive disorders secondary to medical illness. J Geriatr Psychiatry Neurol. 1990;3(3):146–51. https://doi.org/10.1177/089198879000300304.

    Article  CAS  PubMed  Google Scholar 

  104. Lazarus LW, Winemiller DR, Lingam VR, et al. Efficacy and side effects of methylphenidate for poststroke depression. J Clin Psychiatry. 1992;53(12):447–9.

    CAS  PubMed  Google Scholar 

  105. Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry. 2001;9(3):298–303.

    Article  CAS  PubMed  Google Scholar 

  106. Lazarus LW, Moberg PJ, Langsley PR, et al. Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison. Arch Phys Med Rehabil. 1994;75(4):403–6. https://doi.org/10.1016/0003-9993(94)90163-5.

    Article  CAS  PubMed  Google Scholar 

  107. Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry. 1995;152(6):929–31. https://doi.org/10.1176/ajp.152.6.929.

    Article  CAS  PubMed  Google Scholar 

  108. Lavretsky H, Kim MD, Kumar A, et al. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry. 2003;64(12):1410–4. https://doi.org/10.4088/jcp.v64n1202.

    Article  CAS  PubMed  Google Scholar 

  109. Lavretsky H, Park S, Siddarth P, et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry. 2006;14(2):181–5. https://doi.org/10.1097/01.JGP.0000192503.10692.9f.

    Article  PubMed  Google Scholar 

  110. Lavretsky H, Reinlieb M, St. Cyr N, et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(6):561–9. https://doi.org/10.1176/appi.ajp.2014.14070889.

  111. Serafini G, Adavastro G, Canepa G, et al. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. Int J Mol Sci. 2018;19(8):2410. https://doi.org/10.3390/ijms19082410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol. 2008;28(5):593–5. https://doi.org/10.1097/JCP.0b013e31818638a4.

    Article  PubMed  Google Scholar 

  113. Bodkin JA, Zornberg GL, Scott LE, et al. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49–57. https://doi.org/10.1097/00004714-199502000-00008.

    Article  CAS  PubMed  Google Scholar 

  114. Ehrich E, Turncliff R, Du Y, et al. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology. 2015;40(6):1448–55. https://doi.org/10.1038/npp.2014.330.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Emrich HM, Vogt P, Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Ann N Y Acad Sci. 1982;398:108–12. https://doi.org/10.1111/j.1749-6632.1982.tb39483.x.

    Article  CAS  PubMed  Google Scholar 

  116. Fava M, Memisoglu A, Thase ME, et al. Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2016;173(5):499–508. https://doi.org/10.1176/appi.ajp.2015.15070921.

    Article  PubMed  Google Scholar 

  117. Karp JF, Butters MA, Begley AE, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785–93. https://doi.org/10.4088/JCP.13m08725.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Lin C, Karim HT, Pecina M, et al. Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression. Neuroimage Clin. 2019;27(10):1138–52. https://doi.org/10.1016/j.nicl.2019.101679.

    Article  Google Scholar 

  119. Dinoff A, Lynch ST, Sekhri N, et al. A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression. J Affect Disord. 2020;271:91–9. https://doi.org/10.1016/j.jad.2020.03.089.

    Article  CAS  PubMed  Google Scholar 

  120. Aguera-Ortiz L, Claver-Martin MD, Franco-Fernandez MD, et al. Depression in the elderly: consensus statement of the Spanish Psychogeriatric Association. Front Psychiatry. 2020;11:380. https://doi.org/10.3389/fpsyt.2020.00380.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Burris AS, Banks SM, Caster CS, et al. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl. 1992;13:297–304. https://doi.org/10.1002/j.1939-4640.1992.tb00319.x.

    Article  CAS  PubMed  Google Scholar 

  122. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry. 1997;41(3):311–8. https://doi.org/10.1016/S0006-3223(96)00043-1.

    Article  CAS  PubMed  Google Scholar 

  123. Bodani M, Sheehan B, Philpot M. The use of dexamethasone in elderly patients with antidepressant-resistant depressive illness. J Psychopharmacol. 1999;13(2):196–7. https://doi.org/10.1177/026988119901300213.

    Article  CAS  PubMed  Google Scholar 

  124. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc. 2022. https://online.lexi.com. Accessed 7 Oct 2022.

  125. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a huge review. Am J Epidemiol. 2007;165(1):1–13. https://doi.org/10.1093/aje/kwj347.

    Article  PubMed  Google Scholar 

  126. Papakostas GI, Shelton RC, Zajecka JM, et al. L-Methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psych. 2012;169:1267–74. https://doi.org/10.1176/appi.ajp.2012.11071114.

    Article  Google Scholar 

  127. Alpert JE, Papakostas G, Mischoulon D, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004;24(6):661–4.  https://doi.org/10.1097/01.jcp.0000145339.45794.cd.

    Article  CAS  PubMed  Google Scholar 

  128. Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167(8):942–8. https://doi.org/10.1176/appi.ajp.2009.09081198.

    Article  PubMed  Google Scholar 

  129. Geduldig ET, Kellner CH. Electroconvulsive therapy in the elderly: new findings in geriatric depression. Curr Psychiatry Rep. 2016;18(4):40. https://doi.org/10.1007/s11920-016-0674-5.

  130. Canadian Coalition for Senior’s Mental Health. Canadian guidelines on prevention, assessment and treatment of depression among older adults: 2021 guideline update. 2021. https://ccsmh.ca/wp-content/uploads/2021/06/CCSMH_Depression_Guidelines_FINAL_EN.pdf. Accessed 28 Feb 2023.

  131. Spaans, H, Sienaert, P, Bouckaert, F, et al. Speed of remission in elderly patients with depression: electroconvulsive therapy v. medication. Br J Psychiatry. 2015;206(1):67–71. https://doi.org/10.1192/bjp.bp.114.148213.

  132. Socci C, Medda P, Toni C, et al. Electroconvulsive therapy and age: age-related clinical features and effectiveness in treatment resistant major depressive episode. J Affect Disord. 2018;227:627–32. https://doi.org/10.1016/j.jad.2017.11.064.

    Article  PubMed  Google Scholar 

  133. Rapinesi C, Kotzalidis GD, Serata D, et al. Prevention of relapse with maintenance electroconvulsive therapy in elderly patients with major depressive episode. J ECT. 2013;29(1):61–4. https://doi.org/10.1097/YCT.0b013e31826d369a.

    Article  PubMed  Google Scholar 

  134. National Institute of Health and Care Excellence (NICE) (2009) Guidance on the use of electroconvulsive therapy. TA59. https://www.nice.org.uk/guidance/TA59. Accessed 7 Oct 2022.

  135. Lieverse R, Van Someren EJ, Nielen MM, et al. Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial. Arch Gen Psychiatry. 2011;68(1):61–70. https://doi.org/10.1001/archgenpsychiatry.2010.183.

    Article  PubMed  Google Scholar 

  136. Loving RT, Kripke DF, Elliott JA, et al. Bright light treatment of depression for older adults. BMC Psychiatry. 2005;5:41. https://doi.org/10.1186/1471-244X-5-41.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Figiel GS, Epstein C, McDonald WM, et al. The use of rapid-rate transcranial magnetic stimulation (rTMS) in refractory depressed patients. J Neuropsychiatry Clin Neurosci. 1998;10(1):0–25. https://doi.org/10.1175/jnp.10.1.20.

    Article  CAS  Google Scholar 

  138. Fregni F, Marcolin MA, Myczkowski M, et al. Predictors of antidepressant response in clinical trials of transcranial magnetic stimulation. Int J Neuropsychopharmacol. 2006;9(6):641–54. https://doi.org/10.1017/S1461145705006280.

    Article  CAS  PubMed  Google Scholar 

  139. Manes F, Jorge R, Morcuende M, et al. A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. Int Psychogeriatr. 2001;13(2):225–31. https://doi.org/10.1017/s1041610201007608.

    Article  CAS  PubMed  Google Scholar 

  140. Mosimann UP, Marre SC, Werlen S, et al. Antidepressant effects of repetitive transcranial magnetic stimulation in the elderly: correlation between effect size and coil-cortex distance. Arch Gen Psychiatry. 2002;59(6):560–1. https://doi.org/10.1001/archpsyc.59.6.560.

    Article  PubMed  Google Scholar 

  141. Kaster TS, Daskalakis ZJ, Noda Y, et al. Efficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial. Neuropsychopharmacology. 2018;43(11):2231–38. https://doi.org/10.1038/s41386-018-0121-x.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Blumberger DM, Mulsant BH, Fitzgerald PB. A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World J Biol Psychiatry. 2012;13(6):423–35. https://doi.org/10.3109/15622975.2011.579163.

    Article  PubMed  Google Scholar 

  143. Blumberger DM, Maller JJ, Thomson L, et al. Unilateral and bilateral MRI-targeted repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled study. J Psychiatry Neurosci. 2016;41(4):E58–66. https://doi.org/10.1503/jpn.150265.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Trevizol AP, Goldberger KW, Mulsant BH, et al. Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant late-life depression. Int J Geriatr Psychiatry. 2019;34(6):822–27. https://doi.org/10.1002/gps.5091.

    Article  PubMed  PubMed Central  Google Scholar 

  145. Blumberger DM, Mulsant BH, Thorpe KE, et al. Effectiveness of standard sequential bilateral repetitive transcranial magnetic stimulation vs bilateral theta burst stimulation in older adults with depression. JAMA Psychiat. 2022;79(11):1065–73. https://doi.org/10.1001/jamapsychiatry.2022.2862.

    Article  Google Scholar 

  146. American Psychological Association. Depression assessment instruments. https://www.apa.org/depression-guideline/assessment. Accessed 12 Mar 2023.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, Texas Tech University HSC School of Pharmacy-Dallas/Fort Worth, 5920 Forest Park Rd, Dallas, TX, USA

    Amie Taggart Blaszczyk & Monica Mathys

  2. Harrison College of Pharmacy, Auburn University, Auburn, AL, USA

    Jennifer Le

Authors
  1. Amie Taggart Blaszczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Mathys
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jennifer Le
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amie Taggart Blaszczyk.

Ethics declarations

Funding

No funding was received for the publication of this review.

Conflict of interest

Amie Blaszczyk has received consulting fees from AstraZeneca. Monica Mathys and Jennifer Le have no conflicts of interest that are directly relevant to the content of this article.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Authors’ contributions

All authors contributed to the review article conception and original outline. All authors performed literature searches and contributed to the first and subsequent drafts of the manuscript. AB and MM critically revised the final draft. All authors have read and approved the final manuscript, and agree to be accountable for the work.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blaszczyk, A.T., Mathys, M. & Le, J. A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult. Drugs Aging 40, 785–813 (2023). https://doi.org/10.1007/s40266-023-01051-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-023-01051-3

Search

Navigation